Pre-surgery ultra-hypofractionated radiation for retroperitoneal soft tissue sarcoma
Official title: Full-target Ultra-hypofractionated Stereotactic Irradiation Orchestrated With Nodule Boost for Retroperitoneal Sarcoma
Run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT05224934 · Data updated 2026-11-12
This study tests a very short course of pre-surgery high-dose radiation followed by surgery to see if it is safe and manageable for people with retroperitoneal soft tissue sarcoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 1, 2022 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | December 11, 2025 |
| Trial ID | NCT05224934 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with primary retroperitoneal or pelvic soft tissue sarcoma that can be encompassed within one radiation field, who have good performance status (ECOG 0–2), acceptable organ function, and none of the excluded histologic subtypes.
✕Probably not a fit
Patients with excluded histologies (GIST, rhabdomyosarcoma, PNET/small-round-cell sarcomas, osteosarcoma, chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma), tumor extension through the sciatic notch or diaphragm, or inadequate organ function or poor performance/ASA scores are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-arm interventional protocol delivers ultra-hypofractionated stereotactic radiotherapy to patients with primary retroperitoneal or infra-peritoneal soft tissue sarcoma prior to surgical resection. Radiation is planned so all known disease can be included safely within a single treatment field, and strict organ-function and performance-status criteria must be met for enrollment. The trial's primary focus is feasibility and peri-operative complications following the condensed preoperative radiation schedule. The study is conducted at the Radiotherapy Department of the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing.
Why it matters
Potential benefit: If successful, the approach could shorten preoperative treatment time while maintaining safe surgical outcomes and acceptable complication rates.
How similar studies have gone: Ultra-hypofractionated preoperative radiation for retroperitoneal sarcoma is relatively novel with limited direct evidence, though small series and analogous SABR approaches in other sarcoma and abdominal tumors have shown encouraging feasibility and safety signals.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis * Sarcoma not originated from bone structure, abdominal or gynecological viscera * All disease can be included safely within one radiotherapy field * Absence of extension through the sciatic notch or across the diaphragm * Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma * ECOG performance status 0 to 2 * American Society of Anesthesiologist (ASA) score ≤2 * Normal renal function: Calculated Creatinine Clearance ≥50ml/min（by Cockcroft-Gault formula）and functional contralateral kidney by differential renal isotope scan * Normal bone marrow and hepatic function. * Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age * expected life expectancy longer than 5 years * Written consent form was given prior to treatment * Can safely be treated by radiotherapy and surgery Exclusion Criteria: * metastatic disease * Tumor was previously treated by radiotherapy * Involvement of liver, pancreatic head or duodenum
Where it's running
-
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Ning-Ning Lu — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Study coordinator: Ning-Ning Lu
- Email: Ning-Ning.Lu@hotmail.com
- Phone: +868611804268
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients
This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.
-
Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma
This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.
-
Entinostat for pediatric soft tissue sarcoma with PAX abnormalities
This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Preoperative Immunonutrition for bone and soft tissue sarcoma patients
This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.
-
Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma
This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.